Letter to the Editor
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 14, 2025; 31(22): 106636
Published online Jun 14, 2025. doi: 10.3748/wjg.v31.i22.106636
Reevaluating therapeutic strategies in Crohn’s disease: Comparing Modulen and budesonide
Chloe Lahoud, Toni Habib, Elie Bou Sanayeh, Liliane Deeb
Chloe Lahoud, Toni Habib, Elie Bou Sanayeh, Department of Internal Medicine, Staten Island University Hospital, New York, NY 10305, United States
Liliane Deeb, Department of Gastroenterology and Hepatology, Staten Island University Hospital, New York, NY 10305, United States
Co-first authors: Chloe Lahoud and Toni Habib.
Author contributions: Lahoud C and Habib T designed the overall concept and outline of the manuscript and contributed to its writing, they contributed equally as co-first authors; Bou Sanayeh E and Deeb L were responsible for reviewing and editing the manuscript, as well as conducting the literature review.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Elie Bou Sanayeh, MD, Department of Internal Medicine, Staten Island University Hospital, 475 Seaview Avenue, New York, NY 10305, United States. elie.h.bousanayeh@gmail.com
Received: March 4, 2025
Revised: April 3, 2025
Accepted: April 24, 2025
Published online: June 14, 2025
Processing time: 100 Days and 23.3 Hours
Core Tip

Core Tip: Because of the need for effective treatments for mild to moderate Crohn’s disease, nutritional interventions like Modulen have been suggested as a potential option alongside pharmaceutical treatments. Nutritional therapy can improve clinical and endoscopic outcomes, though issues like taste intolerance and adherence remain challenges. Pharmaceutical treatments, such as budesonide, show promise in reducing inflammation, but they may be less effective for mucosal healing. Combining both approaches may offer better management for Crohn’s disease patients. More research is needed to explore long-term benefits and improve patient adherence to treatments.